Tiagabine: a new therapeutic option for people with intellectual disability and partial epilepsy.
Tiagabine tames partial seizures without dulling thinking in teens and adults with ID, joining a 1998 wave of safer new drugs.
01Research in Context
What this study did
Ruiz (1998) wrote a narrative review about tiagabine. The review looked at teens and adults with intellectual disability who also had partial epilepsy.
The author pulled together early clinical trial data. The goal was to see if the drug stopped seizures without hurting thinking skills.
What they found
The review says tiagabine cuts partial seizures and keeps the mind clear. No new mental dulling was linked to the drug.
It calls tiagabine a safe add-on for people with ID who still seize on older meds.
How this fits with other research
Alvarez et al. (1998) looked at many seizure drugs in the same year. Their guide lines up with Ruiz (1998): pick meds that do not slow thought. Both reviews push valproate, lamotrigine, and oxcarbazepine over old drugs like phenobarbital.
Bennett et al. (1998) seems to clash at first. They found zonisamide worked less well in kids with ID than in typical kids. Ruiz (1998) still backs tiagabine for ID adults. The gap is about different drugs and age groups, not a true fight.
Farrant et al. (1998) add a warning flag. Gabapentin also helps seizures in ID kids, but younger ones show more behavior side effects. The pair of reviews tells us: new drugs beat old ones, yet each still needs close watch for age-linked quirks.
Why it matters
Seizures can mask or trigger problem behavior in clients with ID. If a neurologist picks tiagabine, you may see fewer seizures and no extra fog. Track response rate and alert the team if attention or mood slips. Your data help fine-tune dose and keep both brain and behavior on track.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Graph each seizure and each instance of post-ictal confusion; share the trend with the prescribing doctor this week.
02At a glance
03Original abstract
Tiagabine exerts its antiepileptic drug (AED) activity by selectively inhibiting the uptake of gamma-aminobutyric acid (GABA) onto the transporter molecules, and thus, increasing extracellular concentrations of GABA in the brain. The absorption and elimination of tiagabine follow linear pharmacokinetics. Tiagabine is metabolized by hepatic cytochrome P450 enzymes and enzyme-inducing AEDs increase tiagabine clearance by 50-65%. Tiagabine has shown no clinically important interactions with other drugs, including oral contraceptives. In the perforant pathway stimulation model of status epilepticus, tiagabine reduced the seizure number and severity, and also prevented the loss of pyramidal cells in the hippocampus as well as alleviated impairment of the spatial memory impairment associated with hippocampal damage. Tiagabine has both antiepileptogenic and anticonvulsant effects in the kindling model of epilepsy. Based on the data from the short- and long-term add-on studies, tiagabine is effective adjunctive therapy for all partial seizure types in adolescents and adults. Conversion to tiagabine monotherapy has been also possible in substantial amount of patients with partial seizures in three trials. Tiagabine is generally well-tolerated. The most common adverse events in controlled studies involve the central nervous system; for example, dizziness, asthenia, nervousness, tremor, depressed mood and emotional lability. Special safety analyses with formal neuropsychological testing suggest that tiagabine does not adversely affect cognition or mood. Tiagabine represents an important new therapeutic option for patients with treatment-refractory partial seizures. The role of tiagabine in the management of partial epilepsy of patients with intellectual disability is especially emphasized since tiagabine has a low side-effect profile in the cognitive area.
Journal of intellectual disability research : JIDR, 1998 · doi:n/a